e-Drug3D

1827

SAFINAMIDE

INN
SAFINAMIDE

cas 133865-89-1

CLASS

NERVOUS SYSTEM
ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE
MONOAMINE OXIDASE TYPE B (MAO-B) INHIBITOR
BLOCKS THE CATABOLISM OF DOPAMINE
1000-FOLD SELECTIVITY OVER MAO-A

ROUTE (list)

ORAL

ATC code

N04BD03

PK parameters

F 95 PERCENT
Tmax 2.5 HOUR
VD 165 LITER
Cl 4.6 LITER / HOUR
PPB 88 PERCENT
t1/2 23 HOUR

Solubility

SOLUBLE IN WATER BUT SHOWS LOW SOLUBILITY (<0.4 MG/ML) AT PH 6.8 AND 7.5

Target

TARGET MONOAMINE OXIDASE TYPE B (MAO-B)

DrugCentral

Amine oxidase flavin-containing B UNIPROT P27338 MAOB

Download SDF file

Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-

Formula:
C17H19FN2O2

Calculated chemical properties:

MW 302.34
NB_atoms 22
XLogP 2.37
PSA 65.08
NB_HD 3
NB_HA 4
fsp3 0.24
Lipinski(0=no;1=yes) 1

FDA
NDA 207145 (label) INN (SAFINAMIDE MESYLATE) XADAGO (MDD US) APPROVAL= AP YEAR= 2017 NEWMOLECULARENTITY
NDA 215902 (pdf not found) INN (SAFINAMIDE MESYLATE) SAFINAMIDE MESYLATE (AUROBINDO PHARMA) APPROVAL= AP YEAR= 2023 DISCONTINUED
NDA 215945 (pdf not found) INN (SAFINAMIDE) SAFINAMIDE (RK PHARMA) APPROVAL= TA YEAR= 2023
NDA 216020 (pdf not found) INN (SAFINAMIDE) SAFINAMIDE (OPTIMUS PHARMA PRIVATE LTD) APPROVAL= TA YEAR= 2023
NDA 215739 (pdf not found) INN (SAFINAMIDE MESYLATE) SAFINAMIDE MESYLATE (PRINSTON INC) APPROVAL= AP YEAR= 2024
NDA 215978 (pdf not found) INN (SAFINAMIDE MESYLATE) SAFINAMIDE MESYLATE (MSN) APPROVAL= AP YEAR= 2024
NDA 215913 (pdf not found) INN (SAFINAMIDE MESYLATE) SAFINAMIDE MESYLATE (ZENARA) APPROVAL= AP YEAR= 2025